One phase II study evaluating neoadjuvant anti‐PD‐1 antibody plus chemotherapy in patients with resectable gastric or GEJ cancer reported a pCR rate of 19.4%, and the percentage of patients with baseline tumor PD‐L1 CPS >1 in this report was 58.3%.15 Here, CD274 is linked to neoplasm.